Status:
RECRUITING
Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago
Collaborating Sponsors:
Patient-Centered Outcomes Research Institute
Nationwide Children's Hospital
Conditions:
Lennox Gastaut Syndrome
Eligibility:
All Genders
Up to 26 years
Brief Summary
Lennox-Gastaut syndrome is a serious and rare form of epilepsy that begins in infancy and early childhood. Seizures and their consequences need medical attention, emergency encounters, and hospitaliza...
Detailed Description
Background and Significance: Lennox-Gastaut Syndrome (LGS) is a rare developmental-epileptic encephalopathy characterized by life-long refractory seizures which result in frequent utilization of emerg...
Eligibility Criteria
Inclusion
- Patients with the diagnosis of Lennox Gastaut syndrome with medical records at the seven plus eleven pediatric centers
Exclusion
- Patients without Lennox Gastaut Syndrome
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2025
Estimated Enrollment :
4680 Patients enrolled
Trial Details
Trial ID
NCT05374824
Start Date
April 1 2022
End Date
August 31 2025
Last Update
July 16 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
2
C.S. Mott Children's Hospital
Ann Arbor, Michigan, United States, 48109
3
St. Louis Children's Hospital
St Louis, Missouri, United States, 63110
4
Nationwide Children's
Columbus, Ohio, United States, 43205